KELOWNA, BC, Canada -- June 3, 2021 -- InvestorsHub
NewsWire -- Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX)
(the "Company" or "Lexaria"), a global innovator in drug delivery
platforms, announces that remdesivir and ebastine processed with
DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2
virus using an in vitro screening assay in
infected cells in Lexaria study VIRAL-C21-3.
"The main purpose of the study was to confirm that Lexaria's
DehydraTECH formulation and processing methodology did not negate
the known antiviral efficacy of these compounds before proceeding
to larger, planned in vivo efficacy testing,
said Chris Bunka, CEO of Lexaria Bioscience Corp. "These
preliminary findings evidenced SARS-CoV-2 inhibitory performance
commensurate with our expectations warranting ongoing and further
investigation in animal testing."
This study used one of the most widely applied and informative
predictive measures of drug efficacy to measure the half-maximal
inhibitory concentration ("IC50") of the drugs when formulated with
DehydraTECH. This was an important step towards advancing to animal
and ultimately human efficacy testing for the purpose of using
DehydraTECH-processed drugs to treat COVID-19.
This study was performed using a primate cell line, VERO-E6, and
conducted by a leading independent, US biosafety
level 3 testing laboratory that delivers critical services
to government and commercial customers. That third party laboratory
was responsible for study administration, quality control, and
generation of results. Lexaria President John Docherty, Head of
R&D, has verified the information within this press
release.
Lexaria's antiviral study program may also have benefits beyond
COVID-19, including a wide range of other viral disease indications
where improved oral delivery performance is needed. The combined
market for antiviral drugs is projected to be over USD $44 billion
by 2026.1
Remdesivir and ebastine have each shown promise in the fight
against COVID-19. Remdesivir is a well-known nucleotide reverse
transcriptase inhibitor, available under the trade name Veklury®
from Gilead Sciences Inc., that interferes with the SARS-CoV-2
viral replication life cycle and has received emergency use
authorization in many regions of the world for treatment of
COVID-192. Ebastine is an antihistamine drug that has
potent effects in inhibiting the SARS-CoV-2 main protease (Mpro,
also called the 3CL protease) blocking viral entry into human
cells3, together with effects to reduce COVID-19
inflammatory reactions4. Mpro inhibitors are gaining
attention in the fight against COVID-19, as announced by Pfizer
with their novel compound PF-073048145.
Both remdesivir and ebastine are characterized by poor aqueous
solubility and compromised intestinal absorption and
bioavailability when administered orally. Lexaria hopes that its
patented DehydraTECH delivery technology will pave the way for
better performing oral dosage forms of these and other antiviral
drugs, as it has already demonstrated for a range of lipophilic
drug molecules including other antiviral agents such as darunavir
and efavirenz as previously announced. Lexaria is currently
investigating the pharmacokinetic performance of remdesivir and
ebastine in its ongoing animal study VIRAL-A20-2, as well as other
antiviral drugs of interest against SARS-CoV-2 in its additional
ongoing animal study VIRAL-A20-3. The Company will release results
from these studies as well as plans for future in
vivo efficacy modelling as they become available. The
Company is interested in pursuing strategic collaboration
opportunities with established pharmaceutical industry partners who
may be interested in incorporating DehydraTECH technology with
antiviral drugs including and/or similar to those that are
currently being investigated.
The Company is not making any express or implied claims that it
has the ability to eliminate, cure or contain the COVID-19 (or
SARS-2 Coronavirus) at this time.
1 https://www.globenewswire.com/news-release/2020/02/20/1987756/0/en/Antiviral-Drugs-Market-Worth-USD-44-2-billion-by-2026-at-3-2-CAGR-Rising-Prevalence-of-HIV-to-Fuel-Growth-Fortune-Business-Insights.html
2 https://www.nih.gov/news-events/nih-research-matters/final-report-confirms-remdesivir-benefits-covid-19
3 https://www.researchgate.net/publication/341660698_Targeting_the_SARS-CoV-4
4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472874/
5 https://cen.acs.org/pharmaceuticals/drug-discovery/Pfizers-novel-COVID-19-antiviral/98/web/2020/09
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.'s proprietary drug delivery technology,
DehydraTECH™, improves the way active pharmaceutical ingredients
(APIs) enter the bloodstream by promoting healthier oral ingestion
methods and increasing the effectiveness of fat-soluble active
molecules, thereby lowering overall dosing. The Company's
technology can be applied to many different ingestible product
formats, including foods, beverages, oral suspensions, tablets, and
capsules. DehydraTECH has repeatedly demonstrated since 2016 with
cannabinoids and nicotine the ability to increase bio-absorption by
up to 5-10x, reduce time of onset from 1-2 hours to minutes, and
mask unwanted tastes. DehydraTECH is planned to be further
evaluated for orally administered bioactive molecules, including
anti-virals, cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has
licensed DehydraTECH to multiple companies, including a
world-leading tobacco producer for the development of smokeless,
oral-based nicotine products, and for use in industries that
produce cannabinoid beverages, edibles, and oral products. Lexaria
operates a licensed in-house research laboratory and holds a robust
intellectual property portfolio with 19 patents granted and
approximately 60 patents pending worldwide. For more information,
please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING
STATEMENTS
This press release includes forward-looking statements.
Statements as such term is defined under applicable securities
laws. These statements may be identified by words such as
"anticipate," "if," "believe," "plan," "estimate," "expect,"
"intend," "may," "could," "should," "will," and other similar
expressions. Such forward-looking statements in this press release
include, but are not limited to, statements by the Company relating
the Company's ability to carry out research initiatives, receive
regulatory approvals or grants, or experience positive effects or
results from any research or study. Such forward-looking statements
are estimates reflecting the Company's best judgment based upon
current information and involve a number of risks and
uncertainties, and there can be no assurance that the Company will
actually achieve the plans, intentions, or expectations disclosed
in these forward-looking statements. As such, you should not place
undue reliance on these forward-looking statements. Factors which
could cause actual results to differ materially from those
estimated by the Company include, but are not limited to,
government regulation and regulatory approvals, managing and
maintaining growth, the effect of adverse publicity, litigation,
competition, scientific discovery, the patent application and
approval process, potential adverse effects arising from the
testing or use of products utilizing the DehydraTECH technology,
the Company's ability to maintain existing collaborations and
realize the benefits thereof, delays or cancellations of planned
R&D that could occur related to pandemics or for other reasons,
and other factors which may be identified from time to time in the
Company's public announcements and periodic filings with the U.S.
Securities and Exchange Commission on EDGAR. There is no assurance
that any of Lexaria's postulated uses, benefits, or advantages for
the patented and patent-pending technology will in fact be realized
in any manner or in any part. No statement herein has been
evaluated by the Food and Drug Administration (FDA).
Lexaria-associated products are not intended to diagnose, treat,
cure, or prevent any disease. Any forward-looking statements
contained in this release speak only as of the date hereof, and the
Company expressly disclaims any obligation to update any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances, or
otherwise, except as otherwise required by law.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.
INVESTOR CONTACT:
ir@lexariabioscience.com
Phone: 866-221-3341
SOURCE: Lexaria Bioscience Corp.
Lexaria Bioscience (NASDAQ:LEXXW)
過去 株価チャート
から 12 2024 まで 1 2025
Lexaria Bioscience (NASDAQ:LEXXW)
過去 株価チャート
から 1 2024 まで 1 2025
